Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated February 6, 2026, serves as a transaction notification for the month of February 2026. The document discloses a specific securities transaction involving a Person Discharging Managerial Responsibilities (PDMR) rather than providing comprehensive financial results for the period.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It solely reports on a single share purchase transaction:
- Instrument: Ordinary Shares of 31 pence each (ISIN: GB00BN7SWP63).
- Transaction Type: Purchase.
- Volume: 2,500 shares.
- Price: £21.1400 per share.
- Total Value: Approximately £52,850 (calculated from volume and price).
- Date: February 5, 2026.
- Exchange: London Stock Exchange (XLON).
Material Changes
The filing does not contain comparative financial data or material changes to the company's operational performance versus prior periods. The only reported change is the increase in shareholding by the Non-Executive Chair.
Guidance, Outlook, and Risks
The document contains no management commentary, financial guidance, outlook, risk factors, or contingencies. It is a regulatory disclosure of an insider transaction.
Important Facts for Investors to Verify
- Insider Activity: Sir Jonathan Symonds, Non-Executive Chair, purchased 2,500 ordinary shares on February 5, 2026.
- Transaction Price: The purchase was executed at £21.1400 per share.
- Scope Limitation: This filing does not contain quarterly or annual financial performance data; investors should refer to Form 20-F or other earnings releases for financial metrics.